The short version of immunomodulatory peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-19. Anything still debated is marked as such rather than presented as settled.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
1985–1987 – 1.3 L (1,296 cc) E3, 2 barrel, 8-valve, 74 PS (54 kW; 73 hp) Gross / 10.5 kg⋅m (103 N⋅m; 76 lb⋅ft) 1987–1989 – 1.3 L (1,323 cc) B3, 2 barrel, 8-valve, 67 PS (49 kW; 66 hp) Net / 10.4 kg⋅m (102 N⋅m; 75 lb⋅ft) 1985–1987 – 1.5 L (1,490 cc) E5, 2 barrel carburettor, 8-valve, 85 PS (63 kW; 84 hp) Gross / 12.3 kg⋅m (121 N⋅m; 89 lb⋅ft) Gross – Net rating 70 PS (51 kW; 69 hp) / 11.2 kg⋅m (110 N⋅m; 81 lb⋅ft) 1985–1987 – 1.5 L (1,490 cc) E5, EGi, 8-valve, 95 PS (70 kW; 94 hp) Gross/12.6 kg⋅m (124 N⋅m; 91 lb⋅ft) Gross – Net rating 76 PS (56 kW; 75 hp) / 11.6 kg⋅m (114 N⋅m; 84 lb⋅ft) 1985–1987 – 1.5 L (1,490 cc) E5T, turbo EGi, 8-valve, 115 PS (85 kW; 113 hp) Gross / 16.5 kg⋅m (162 N⋅m; 119 lb⋅ft) 1987–1989 – 1.5 L (1,498 cc) B5, 2 barrel, 12-valve, 76 PS (56 kW; 75 hp) Net / 11.4 kg⋅m (112 N⋅m; 82 lb⋅ft) 1987–1989 – 1.6 L (1,597 cc) B6, EGi, 8-valve, 85 PS (63 kW; 84 hp) Net / 12.5 kg⋅m (123 N⋅m; 90 lb⋅ft) 1986–1989 – 1.6 L (1,597 cc) B6D, EGi, 16-valve, 110 PS (81 kW; 108 hp) Net / 13.5 kg⋅m (132 N⋅m; 98 lb⋅ft) 1985–1989 – 1.6 L (1,597 cc) B6T, turbo EGi, 16-valve, 140 PS (103 kW; 138 hp) Net / 19.0 kg⋅m (186 N⋅m; 137 lb⋅ft) 1985–1989 – 1.7 L (1,720 cc) PN, diesel, 8-valve, 59 PS (43 kW; 58 hp) Gross / 10.8 kg⋅m (106 N⋅m; 78 lb⋅ft) Gross – Net rating 55 PS (40 kW; 54 hp) / 10.2 kg⋅m (100 N⋅m; 74 lb⋅ft), 1987–1989; Net rating: 58 PS (43 kW; 57 hp) / 10.7 kg⋅m (105 N⋅m; 77 lb⋅ft)
In recent years the Microfluidizer method has gained popularity in cell disruption due to its ease of use and efficiency at disrupting many different kinds of cells. The Microfluidizer technology was licensed from a company called Arthur D. Little and was first developed and utilized in the 1980s, initially starting as a tool for liposome creation. It has since been used in other applications such as cell disruption nanoemulsions, and solid particle size reduction, among others. By using microchannels with fixed geometry, and an intensifier pump, high shear rates are generated that rupture the cells. This method of cell lysis can yield breakage of over 90% of E. coli cells. Many proteins are extremely temperature-sensitive, and in many cases can start to denature at temperatures of only 4 degrees Celsius. Within the microchannels, temperatures exceed 4 degrees Celsius, but the machine is designed to cool quickly so that the time the cells are exposed to elevated temperatures is extremely short (residence time 25 ms-40 ms). Because of this effective temperature control, the Microfluidizer yields higher levels of active proteins and enzymes than other mechanical methods when the proteins are temperature-sensitive. Viscosity changes are also often observed when disrupting cells. If the cell suspension viscosity is high, it can make downstream handling—such as filtration and accurate pipetting—quite difficult. The viscosity changes observed with a Microfluidizer are relatively low, and decreases with further additional passes through the machine.
=== Endogenous production and effects === In the 1950s, the endogenous production of psychoactive agents was considered to be a potential explanation for the hallucinatory symptoms of some psychiatric diseases; this is known as the transmethylation hypothesis. Several speculative and yet untested hypotheses suggest that endogenous DMT is produced in the human brain and is involved in certain psychological and neurological states. DMT is naturally occurring in small amounts in rat brains, human cerebrospinal fluid, and other tissues of humans and other mammals. Further, mRNA for the enzyme necessary for the production of DMT, INMT, are expressed in the human cerebral cortex, choroid plexus, and pineal gland, suggesting an endogenous role in the human brain. In 2011, Nicholas Cozzi of the University of Wisconsin School of Medicine and Public Health, and three other researchers, concluded that INMT, an enzyme that is associated with the biosynthesis of DMT and endogenous hallucinogens is present in the non-human primate (rhesus macaque) pineal gland, retinal ganglion neurons, and spinal cord. Neurobiologist Andrew Gallimore suggested in 2013 that while DMT might not have a modern neural function, it may have been an ancestral neuromodulator once secreted in psychedelic concentrations during REM sleep, a function now lost.
In 1958, British developmental psychologist John Bowlby published the paper "the Nature of the Child's Tie to his Mother," in which the precursory concepts of "attachment theory" were developed. This included the development of the concept of the affectional bond, which is based on the universal tendency for humans to attach, i.e. to seek closeness to another person and to feel secure when that person is present. Attachment theory has some of its origins in the observation of and experiments with animals, but is also based on observations of children who had missed typical experiences of adult care. Much of the early research on attachment in humans was done by John Bowlby and his associates. Bowlby proposed that babies have an inbuilt need from birth to make emotional attachments, i.e. bonds, because this increases the chances of survival by ensuring that they receive the care they need. Bowlby did not describe mutuality in attachment. He stated that attachment by mother was a pathological inversion and described only behaviors of the infant. Many developmental specialists elaborated Bowlby's ethological observations. However, neither Bowlby's proximity seeking (not possible for human infants prior to walking) nor subsequent descriptions of caregiver–infant mutuality with emotional availability and synchrony with emotional modulation include the enduring motivation of attachment into adult life. The enduring motivation is the desire to control a pleasantly surprising transformation that is the route of belief in effectiveness by humans.
Sources: en.wikipedia.org
A very important modification of eukaryotic pre-mRNA is RNA splicing. The majority of eukaryotic pre-mRNAs consist of alternating segments called exons and introns. During the process of splicing, an RNA-protein catalytical complex known as spliceosome catalyzes two transesterification reactions, which remove an intron and release it in form of lariat structure, and then splice neighbouring exons together. In certain cases, some introns or exons can be either removed or retained in mature mRNA. This so-called alternative splicing creates series of different transcripts originating from a single gene. Because these transcripts can be potentially translated into different proteins, splicing extends the complexity of eukaryotic gene expression and the size of a species proteome. Extensive RNA processing may be an evolutionary advantage made possible by the nucleus of eukaryotes. In prokaryotes, transcription and translation happen together, whilst in eukaryotes, the nuclear membrane separates the two processes, giving time for RNA processing to occur.
During the corresponding period some 8,578 actual downloads of the software were independently logged via the same route at the AIDA Website, giving a response rate for this survey of 45%. Responses were received from participants in 66 countries — over half of these (n=2,137; 55.3%) were from the United States and the United Kingdom. There were 2,318 responses (60.0%) received from people with diabetes and 443 (11.5%) from relatives of patients, with fewer responses from doctors, students, diabetes educators, nurses, pharmacists, and other end users. The authors concluded that the study highlighted "considerable interest amongst patients and their relatives to learn more about balancing insulin and diet in diabetes, as well as possibly to get more involved in self-management of insulin dosages. More computer applications that can cater for this interest in diabetes patient self-care need to be developed and made available. The Internet provides an ideal medium for the distribution of such educational tools".
The M242 Bushmaster chain gun is a 25 mm (25×137mm) single-barrel chain-driven autocannon. It is used extensively by the U.S. military, such as in the Bradley fighting vehicle, as well as by other NATO members and some other nations in ground combat vehicles and various watercraft. Hughes Helicopters in Culver City, California, was the original designer and manufacturer. As of 2019, Northrop Grumman Innovation Systems produces the gun. It is an externally-powered, chain-driven, single-barrel weapon that may be fired in semi-automatic, burst, or automatic modes. It is fed by a metallic link belt and has dual-feed capability. The term chain gun derives from the use of a roller chain that drives the bolt back and forth. The gun can destroy lightly armored vehicles and aerial targets such as helicopters and other slow-flying aircraft. It can also apply suppression fire against exposed troops, dug-in positions, and occupied built-up areas. The standard rate of fire is 200 rounds per minute. The weapon has an effective range of 2,000 metres (6,600 ft), depending on the type of ammunition used. With over 11,000 units sold worldwide, it is one of the most successful modern autocannons.
== History == The use of snail slime in cosmetics and pharmaceutical applications dates back to ancient Greece, where it was recommended as a treatment for skin inflammation. Early practices involved crushing secretions from brown garden snails to help alleviate inflammatory skin conditions. This approach is part of a broader tradition known as zootherapy, which has existed since ancient Mesopotamia and Egypt and involves the use of animal-based remedies for healing. Additionally, snails were known to be high in nutrients and as a delicacy to be eaten.
It is a flexible tool for creating ROC graphs, sensitivity/specificity curves, area under curve and precision/recall curve. The parametrization can be visualized by coloring the curve according to cutoff. WebCDK: A web interface for the CDK library which is used for predicting descriptors of chemicals. Pharmacokinetics: This data analysis determines the relationship between the dosing regimen and the body's exposure to the drug as measured by the drug's nonlinear concentration time curve. It includes a function to calculate area under this curve. It also includes functions for half-life estimation for a biexponential model, and a two phase linear regression.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
The lyophilized solid is normally held at 2 to 8 °C in a sealed, light-protected container. Dry storage limits both hydrolysis and microbial growth. Material kept this way remains stable for the shelf life stated by the supplier.